Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.antiviral.2019.104637
Title: | Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection | Authors: | Loe, MWC Lee, RCH Chu, JJH |
Keywords: | Antiviral FDA-approved compounds High-throughput screening Zika |
Issue Date: | 1-Dec-2019 | Publisher: | Elsevier BV | Citation: | Loe, MWC, Lee, RCH, Chu, JJH (2019-12-01). Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection. Antiviral Research 172 : 104637-. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2019.104637 | Abstract: | © 2019 Elsevier B.V. Zika virus (ZIKV) is a mosquito-borne virus that has risen to prominence as a significant threat to public health in the recent decade. Since its re-emergence in 2007, ZIKV has spread at an alarming rate and has since become endemic to multiple regions around the world. Infections are primarily asymptomatic, however the virus has become associated with the development of severe neurological complications such as Guillain–Barré syndrome (GBS) and congenital microcephaly. At present, there are currently no approved antivirals for ZIKV infections. In this study, we utilised a phenotype-based screening platform to perform a high-throughput screen on a 1172-compound US FDA-approved drug library to identify potential novel inhibitors against ZIKV. Candesartan cilexetil, an angiotensin II receptor inhibitor, displayed potent inhibition effects against ZIKV and subsequent downstream time-course studies revealed that it targets a post-entry stage(s) of the ZIKV replication cycle. Moreover, candesartan cilexetil also inhibited viral RNA production and viral protein synthesis. Candesartan cilexetil also exhibited antiviral effects against Dengue virus serotype-2 (DENV2), Kunjin virus (KUNV) and Chikungunya virus (CHIKV), indicating that its antiviral properties may not be restricted to ZIKV. Our study has demonstrated for the first time the potential application of candesartan cilexetil as an antiviral. | Source Title: | Antiviral Research | URI: | https://scholarbank.nus.edu.sg/handle/10635/173210 | ISSN: | 01663542 18729096 |
DOI: | 10.1016/j.antiviral.2019.104637 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
6.pdf | Accepted version | 2.94 MB | Adobe PDF | OPEN | Post-print | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.